# A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Source: https://onco.cc/trials/nct06686576/  
OnCo record `nct06686576` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing QL1706 in colorectal cancer, now recruiting.

## Summary

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer is a phase 3 interventional study registered as NCT06686576, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase Ib/III, Open-Label, Randomised Study of Neoadjuvant QL1706 Versus Standard of Care in Participants With Untreated of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer. Planned enrolment is 363 participants (estimated). The study started in 2024-12-12 and primary completion is expected in 2030-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06686576
- Phase: 3
- Setting: A Phase Ib/III, Open-Label, Randomized Study of Neoadjuvant QL1706 Versus Standard of Care in Participants With Untreated of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
- Sponsor: Qilu Pharmaceutical
- Enrolled: 363

## Sources

- ClinicalTrials.gov NCT06686576: https://clinicaltrials.gov/study/NCT06686576

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- drugs: [QL1706](https://onco.cc/drugs/ql1706/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06686576.json